A share price of Amicus Therapeutics Inc [FOLD] is currently trading at $10.17, up 1.50%. An important factor to consider is whether the stock is rising or falling in short-term value. The FOLD shares have gain 2.52% over the last week, with a monthly amount drifted -2.96%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on May 30, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $18. Previously, Guggenheim upgraded its rating to Buy on May 14, 2024, and kept the price target unchanged to $13. On December 19, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $20 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $14 on September 09, 2022. SVB Leerink upgraded its rating to Outperform for this stock on January 14, 2022, and upped its price target to $16. In a note dated November 15, 2021, Stifel upgraded an Buy rating on this stock and boosted its target price from $12 to $16.
Amicus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $9.02 and $14.57. Currently, Wall Street analysts expect the stock to reach $15.33 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $10.17 at the most recent close of the market. An investor can expect a potential return of 50.74% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
Trailing Twelve Months sales for Amicus Therapeutics Inc [NASDAQ:FOLD] were 423.49M which represents 27.97% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.33%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -1.1 and Total Capital is -0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.02 points at the first support level, and at 9.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.27, and for the 2nd resistance point, it is at 10.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Amicus Therapeutics Inc [NASDAQ:FOLD] is 3.03. On the other hand, the Quick Ratio is 2.61, and the Cash Ratio is 1.48. Considering the valuation of this stock, the price to sales ratio is 7.11, the price to book ratio is 23.05.
Transactions by insiders
Recent insider trading involved Campbell Bradley L, President and CEO, that happened on Jul 01 ’24 when 1400.0 shares were sold. President and CEO, Campbell Bradley L completed a deal on Jun 03 ’24 to sell 7500.0 shares. Meanwhile, President and CEO Campbell Bradley L sold 7500.0 shares on May 01 ’24.
